Semaglutide (February 11, 2024) Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation (May 17, 2025) OZEMPIC (semaglutide) injection, for subcutaneous use
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
1 In patients with diabetes mellitus, GLP-1 RAs improve glycaemic control, and as single agents do not increase the risk of hypoglycaemia
If you are travelling internationally, you may need to take your injection slightly earlier or later to maintain consistency with your new time zone
Song G, Yang D, Wang Y, de Graaf C, Zhou Q, Jiang S, et al
The coprimary endpoints were the percentage change in body weight and weight reduction of at least 5%